Ciprofloxacin (UTI) — Discount Pricing

Other medications in Urology

• Desmopressin Nasal
• Doxazosin
• Dutasteride
• Dutasteride/Tamsulosin
• Fesoterodine
• Finasteride
• Mirabegron
• Oxybutynin

About Ciprofloxacin (UTI)

Urinary Tract Infections (UTIs) can be painful, but ciprofloxacin offers an effective solution. This powerful antibiotic is a common prescription for bacterial UTIs, helping you find relief quickly. With TheDrugClub, you can significantly reduce the cost of your ciprofloxacin prescription, making essential treatment more affordable.

What Ciprofloxacin Treats

Ciprofloxacin is a widely prescribed antibiotic primarily used to treat a variety of bacterial infections, with urinary tract infections (UTIs) being one of its most common applications. UTIs occur when bacteria, typically from the bowel, enter the urinary tract and multiply. Ciprofloxacin is effective against many of the common bacterial strains responsible for these infections, including *E. coli*. Beyond UTIs, ciprofloxacin can also be prescribed for other bacterial infections like respiratory tract infections, skin infections, bone and joint infections, and certain sexually transmitted infections, although its use for some of these has become more restricted due to concerns about antibiotic resistance and side effects. Always consult your healthcare provider to determine if ciprofloxacin is the right treatment for your specific infection.

How Ciprofloxacin Works

Ciprofloxacin belongs to a class of antibiotics called fluoroquinolones. Its mechanism of action is quite specific and powerful: it works by inhibiting two bacterial enzymes, DNA gyrase and topoisomerase IV, which are crucial for bacterial DNA replication, transcription, repair, and recombination. By blocking these enzymes, ciprofloxacin prevents bacteria from multiplying and repairing their genetic material, ultimately leading to the death of the bacterial cells

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ciprofloxacin (UTI) is approved for (FDA label)

Ciprofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: • Skin and Skin Structure Infections ( 1.1 ) • Bone and Joint Infections ( 1.2 ) • Complicated Intra-Abdominal Infections ( 1.3 ) • Infectious Diarrhea ( 1.4 ) • Typhoid Fever (Enteric Fever) ( 1.5 ) • Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) • Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) • Plague in adult and pediatric patients ( 1.8 ) • Chronic Bacterial Prostatitis ( 1.9 ) • Lower Respiratory Tract Infections ( 1.10 ) o Acute Exacerbation of Chronic Bronchitis • Urinary Tract Infections ( 1.11 ) o Urinary Tract Infections (UTI) o Acute Uncomplicated Cystitis o Complicated UTI and Pyelonephritis in Pediatric Patients • Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs, ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 ) 1.1 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli , Klebsiella pneumoniae , Enterobacter cloacae , Proteus mirabilis , Proteus vulgaris , Providencia stuartii , Morganella morganii , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus aureus , methicillin-susceptible Staphylococcus epidermidis , or Streptococcus pyogenes . 1.2 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.3 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.4 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni , Shigella boydii † , Shigella dysenteriae , Shigella flexneri or Shigella sonnei † when antibacterial therapy is indicated. † Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.5 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi . The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.6 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see Warnings and Precautions (5.17) ]. 1.7 Inhalational Anthrax (Post-Exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.

Source: Read the full FDA label on DailyMed. Label effective date: August 11, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ciprofloxacin (UTI) (FDA label)

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS • Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1) ] including: o Tendinitis and tendon rupture [see Warnings and Precautions (5.2) ] o Peripheral neuropathy [see Warnings and Precautions (5.3) ] o Central nervous system effects [see Warnings and Precautions (5.4) ] • Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones, including ciprofloxacin tablets, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1) ]. Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid ciprofloxacin in patients with known history of myasthenia gravis [see Warnings and Precautions (5.5) ] . • Because fluoroquinolones, including ciprofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.16) ] , reserve ciprofloxacin tablets for use in patients who have no alternative treatment options for the following indications: o Acute exacerbation of chronic bronchitis [see Indications and Usage (1.10) ] o Acute uncomplicated cystitis [see Indications and Usage (1.11) ] o Acute sinusitis [see Indications and Usage (1.12) ] WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 922e9f5c-cc59-4d9e-bf42-a4b900d077ed. SPL document ID: b0fc7f48-0bd0-487b-a66d-013cd93554d2. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ciprofloxacin (UTI) (FDA label)

• Tablets: 250 mg, 500 mg, 750 mg ( 3 ) 3.1 Tablets • For 250 mg: White colored, biconvex, circular, film coated tablets, debossed 'P' on one side and '250' on the other side. • For 500 mg: White colored, biconvex, capsule shaped, film coated tablets, debossed 'P' on one side and '500' on the other side. • For 750 mg: White colored, biconvex, capsule shaped, film coated tablets, debossed 'P' on one side and '750' on the other side.

Source: FDA prescribing information (DailyMed). Set ID: 922e9f5c-cc59-4d9e-bf42-a4b900d077ed. SPL document ID: b0fc7f48-0bd0-487b-a66d-013cd93554d2. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ciprofloxacin (UTI) (FDA label)

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: • Disabling and Potentially Irreversible Serious Adverse Reactions [see Warnings and Precautions (5.1)] • Tendinitis and Tendon Rupture [see Warnings and Precautions (5.2) ] • Peripheral Neuropathy [see Warnings and Precautions (5.3) ] • Central Nervous System Effects [see Warnings and Precautions (5.4) ] • Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.5) ] • Other Serious and Sometimes Fatal Adverse Reactions [see Warnings and Precautions (5.6) ] • Hypersensitivity Reactions [see Warnings and Precautions (5.7) ] • Hepatotoxicity [see Warnings and Precautions (5.8) ] • Risk of Aortic Aneurysm and Dissection [see Warnings and Precautions (5.9 )] • Serious Adverse Reactions with Concomitant Theophylline [see Warnings and Precautions (5.10) ] • Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.11) ] • Prolongation of the QT Interval [see Warnings and Precautions (5.12) ] • Musculoskeletal Disorders in Pediatric Patients [see Warnings and Precautions (5.13) ] • Photosensitivity/Phototoxicity [see Warnings and Precautions (5.14) ] • Development of Drug Resistant Bacteria [see Warnings and Precautions (5.15) ] The most common adverse reactions ≥ 1% were nausea, diarrhea, liver function tests abnormal, vomiting, and rash. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 922e9f5c-cc59-4d9e-bf42-a4b900d077ed. SPL document ID: b0fc7f48-0bd0-487b-a66d-013cd93554d2. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ciprofloxacin (UTI) (FDA label)

• Known hypersensitivity to ciprofloxacin or other quinolones ( 4.1 , 5.6 , 5.7 ) • Concomitant administration with tizanidine ( 4.2 ) 4.1 Hypersensitivity Ciprofloxacin tablet is contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antibacterials, or any of the product components [see Warnings and Precautions (5.7) ]. 4.2 Tizanidine Concomitant administration with tizanidine is contraindicated [see Drug Interactions (7) ].

Source: FDA prescribing information (DailyMed). Set ID: 922e9f5c-cc59-4d9e-bf42-a4b900d077ed. SPL document ID: b0fc7f48-0bd0-487b-a66d-013cd93554d2. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ciprofloxacin (UTI) (FDA label)

• Hypersensitivity and other serious reactions: Serious and sometimes fatal reactions (for example, anaphylactic reactions) may occur after the first or subsequent doses of ciprofloxacin tablets. Discontinue ciprofloxacin tablets at the first sign of skin rash, jaundice or any sign of hypersensitivity. ( 4.1 , 5.6, 5.7 ) • Hepatotoxicity: Discontinue immediately if signs and symptoms of hepatitis occur. ( 5.8 ) • Clostridioides difficile -associated diarrhea: Evaluate if colitis occurs. ( 5.11 ) • QT Prolongation: Prolongation of the QT interval and isolated cases of torsade de pointes have been reported.

Source: FDA prescribing information (DailyMed). Set ID: 922e9f5c-cc59-4d9e-bf42-a4b900d077ed. SPL document ID: b0fc7f48-0bd0-487b-a66d-013cd93554d2. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ciprofloxacin (UTI) (FDA label)

Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Co-administration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug. Table 11: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [ seeContraindications (4.2) ]. Theophylline Avoid Use (Plasma Exposure Likely to be Increased and Prolonged) Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions.

Source: FDA prescribing information (DailyMed). Set ID: 922e9f5c-cc59-4d9e-bf42-a4b900d077ed. SPL document ID: b0fc7f48-0bd0-487b-a66d-013cd93554d2. Label effective date: August 11, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.